Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly EBITDA Margin of 1022.65% in Q1 2026, up 33.05% quarter-over-quarter from 1527.57% in Q4 2025, and down 904.0% on a YoY basis from 127.19% in Q1 2025.
Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 1022.65% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 904.0% year-over-year to 1022.65%; the TTM figure through Mar 2026 stood at 837.5% (down 10958.0% YoY), while the FY2025 annual figure was 823.03%, down 11863.0% from the prior year.
- EBITDA Margin was 1022.65% for Q1 2026 at Aclaris Therapeutics, up from 1527.57% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2.66% in Q4 2023 to a low of 1622.58% in Q2 2023.
- Historically, EBITDA Margin has averaged 787.77% across 5 years, with a median of 865.56% in 2025.
- Biggest YoY gain for EBITDA Margin was 122182 bps in 2024; the steepest drop was 104914 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 349.12% in 2022, then surged by 99 bps to 2.66% in 2023, then plunged by 39388 bps to 1051.81% in 2024, then slumped by 45 bps to 1527.57% in 2025, then surged by 33 bps to 1022.65% in 2026.
- The last three EBITDA Margin figures came in at 1022.65% (Q1 2026), 1527.57% (Q4 2025), and 439.5% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | -1,022.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,022.65% |
| Dec 31, 2025 | -1,527.57% |
| Sep 30, 2025 | -439.50% |
| Jun 30, 2025 | -865.56% |
| Mar 31, 2025 | -1,013.61% |
| Dec 31, 2024 | -1,051.81% |
| Sep 30, 2024 | -154.07% |
| Jun 30, 2024 | -400.76% |
| Mar 31, 2024 | -717.22% |
| Dec 31, 2023 | -2.66% |
| Sep 30, 2023 | -315.44% |
| Jun 30, 2023 | -1,622.58% |
| Mar 31, 2023 | -1,092.44% |
| Dec 31, 2022 | -349.12% |
| Sep 30, 2022 | -105.64% |
| Jun 30, 2022 | -1,366.88% |
| Mar 31, 2022 | -1,344.60% |
| Dec 31, 2021 | -1,533.98% |
| Sep 30, 2021 | -1,263.71% |
| Jun 30, 2021 | -998.08% |